AMGEN INC (1AMGN.MI) Stock Price, Forecast & Analysis
Europe - BIT:1AMGN - US0311621009 - Common Stock
1AMGN.MI Key Statistics, Chart & Performance
The current stock price of 1AMGN.MI is 293.45 EUR. In the past month the price decreased by -7.98%.
1AMGN.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 71.89 | 47.36B | ||
| ARGX.BR | ARGENX SE | 72.88 | 48.01B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.63B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.33B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.24 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 876.56M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| IVA.PA | INVENTIVA SA | N/A | 494.46M | ||
| FYB.DE | FORMYCON AG | N/A | 366.65M | ||
| VLA.PA | VALNEVA SE | N/A | 332.16M |
Related stock screener links
About 1AMGN.MI
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA US
Employees: 28000
Phone: 18054471000
AMGEN INC / 1AMGN.MI FAQ
Can you describe the business of AMGEN INC?
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Can you provide the latest stock price for AMGEN INC?
The current stock price of 1AMGN.MI is 293.45 EUR. The price increased by 14.38% in the last trading session.
Does AMGEN INC pay dividends?
AMGEN INC (1AMGN.MI) has a dividend yield of 3.22%. The yearly dividend amount is currently 7.79.
What is the ChartMill technical and fundamental rating of 1AMGN stock?
1AMGN.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for 1AMGN.MI stock?
40 analysts have analysed 1AMGN.MI and the average price target is 274.32 EUR. This implies a price decrease of -6.52% is expected in the next year compared to the current price of 293.45.
Can you provide the PE ratio for 1AMGN stock?
The PE ratio for AMGEN INC (1AMGN.MI) is 15.57. This is based on the reported non-GAAP earnings per share of 18.85 and the current share price of 293.45 EUR.
Can you provide the number of employees for AMGEN INC?
AMGEN INC (1AMGN.MI) currently has 28000 employees.
1AMGN.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1AMGN.MI.
1AMGN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1AMGN.MI. While 1AMGN.MI belongs to the best of the industry regarding profitability, there are concerns on its financial health.
1AMGN.MI Financial Highlights
Over the last trailing twelve months 1AMGN.MI reported a non-GAAP Earnings per Share(EPS) of 18.85. The EPS increased by 17.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 18.96% | ||
| ROA | 7.53% | ||
| ROE | 89.11% | ||
| Debt/Equity | 7.24 |
1AMGN.MI Forecast & Estimates
40 analysts have analysed 1AMGN.MI and the average price target is 274.32 EUR. This implies a price decrease of -6.52% is expected in the next year compared to the current price of 293.45.
For the next year, analysts expect an EPS growth of 8.45% and a revenue growth 7.54% for 1AMGN.MI